ArticleEcho research and practice2026
The diagnostic value of left atrial stiffness for heart failure with preserved ejection fraction in patients with paroxysmal atrial fibrillation.
Article in Echo research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05266144 (A Prospective Cohort Study of Atrial Fibrillation Patients Treated With Catheter Ablation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Cohort Study of Atrial Fibrillation Patients Treated With Catheter Ablation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
aimsLeft atrial (LA) function is impaired in both atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Diagnosing HFpEF remains challenging, especially in AF patients. This study aims to evaluate whether LA stiffness (LAS) can facilitate the diagnosis of HFpEF in patients with paroxysmal atrial fibrillation (pxAF). METHODS AND
resultsA total of 187 pxAF patients were enrolled in the discovery cohort and underwent baseline transthoracic echocardiography (TTE). LAS was measured in all patients, and HFpEF was ascertained based on the H2FPEF score (44 high-probability of HFpEF [hp-HFpEF], 143 low-probability of HFpEF [lp-HFpEF]). The left ventricular diastolic function and LA function were significantly altered in the hp-HFpEF group compared to the lp-HFpEF group. Among all echocardiographic indices, the ratio of E/MVE’ to 3D LAEF as a surrogate of LAS showed the greatest diagnostic performance in distinguishing hp-HFpEF from lp-HFpEF in pxAF patients (AUC = 0.862, 95% CI 0.801–0.922, p < 0.001), with an optimal cutoff value of 0.27. Combining MVE’ and LAS revealed the highest diagnostic efficiency (LR + 12.18) compared to any single variable. The discriminatory value of LAS with MVE’ was further verified in the validation cohort with an LR + of 7.18.
conclusionLAS analyzed by conventional echocardiography combined with MVE’ is a non-invasive, decision-support approach for discriminating hp-HFpEF from lp-HFpEF in pxAF patients. The clinical trial registration number: ClinicalTrials.gov NCT05266144.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.